Indaptus Q2 2023 cash $19.7M, Phase 1 trial advances; CMO appointed

Indaptus Therapeutics, Inc.

2023-Q2 EPS reported -$0.89

Cash and marketable securities $19.7M as of June 30, 2023; runway into Q2 2024.
Phase 1 trial (Decoy20) completed first cohort, authorized to advance to second; evidence of immune activation.
Appointed Roger Waltzman, M.D. as Chief Medical Officer, effective Aug 7, 2023.
Q2 2023 net loss per share $0.39 vs $0.46 prior year; G&A down to $2.0M.
Patent allowances in Brazil and India expanded IP protection to 32 countries.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Indaptus Therapeutics, Inc. reported second quarter ended June 30, 2023 results: EPS Loss per share for the three months ended June 30, 2023 was approximately $0.39.

Period: second quarter ended June 30, 2023
EPS: Loss per share for the three months ended June 30, 2023 was approximately $0.39
Result: reported results

Exact text from the filing

Loss per share for the three months ended June 30, 2023 was approximately $0.39

View on SEC.gov

Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-028054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.